What are the key takeaways from this BioCentury This Week episode?

Key insights include: **GSK's Wrap acquisition strategy:** GSK paid $2.2B ($1.9B net of cash) for Wrap Therapeutics, a company that in-licensed its food allergy prophylaxis asset from Chinese firm JU just 13 months prior for $35M upfront plus ~$700M in milestones. The Phase 2b asset targets a dosing advantage over Xolair, with results expected within one year.; **China-to-West asset licensing model:** Western pharma companies are actively licensing and acquiring assets originating from Chinese biotechs, but geopolitical barriers make full company acquisitions of Chinese firms effectively off the table. The practical playbook is to take the asset, not the company, avoiding regulatory and political entanglement while capturing innovation.; **TAC field expansion beyond proteasome:** Next-generation targeted protein degradation now spans four distinct mechanisms: classical PROTAC E3 ligase recruitment via cereblon, new E3 ligases like TRIM21 that selectively degrade aggregated proteins while sparing monomers, lysosomal degraders targeting extracellular proteins via bispecific antibodies, and induced proximity approaches enabling phosphorylation and protein stabilization beyond degradation.

What did Danielle Golovin and Simone Fishburne discuss on BioCentury This Week?

BioCentury This Week covers JPMorgan Healthcare Conference takeaways, GSK's $2.2B acquisition of Wrap Therapeutics targeting food allergies, next-generation targeted protein degradation technologies including TACs and lysosomal degraders, Trump's push to codify Most Favored Nation drug pricing into legislation, and pediatric priority review voucher reauthorization progress in Congress. Key topics include: **GSK's Wrap acquisition strategy:** GSK paid $2.2B ($1.9B net of cash) for Wrap Therapeutics, a company that in-licensed its food allergy prophylaxis asset from Chinese firm JU just 13 months prior for $35M upfront plus ~$700M in milestones. The Phase 2b asset targets a dosing advantage over Xolair, with results expected within one year.; **China-to-West asset licensing model:** Western pharma companies are actively licensing and acquiring assets originating from Chinese biotechs, but geopolitical barriers make full company acquisitions of Chinese firms effectively off the table. The practical playbook is to take the asset, not the company, avoiding regulatory and political entanglement while capturing innovation..

How long is this episode of BioCentury This Week?

This episode is 30 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

BioCentury This Week

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

January 21, 2026

30 min episode · 2 min read

Danielle Golovin,Simone Fishburne,Steve Usdin

Episode

30 min

Read time

2 min

Topics

Career Growth, Health & Wellness, Fundraising & VC

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓GSK's Wrap acquisition strategy: GSK paid $2.2B ($1.9B net of cash) for Wrap Therapeutics, a company that in-licensed its food allergy prophylaxis asset from Chinese firm JU just 13 months prior for $35M upfront plus ~$700M in milestones. The Phase 2b asset targets a dosing advantage over Xolair, with results expected within one year.
✓China-to-West asset licensing model: Western pharma companies are actively licensing and acquiring assets originating from Chinese biotechs, but geopolitical barriers make full company acquisitions of Chinese firms effectively off the table. The practical playbook is to take the asset, not the company, avoiding regulatory and political entanglement while capturing innovation.
✓TAC field expansion beyond proteasome: Next-generation targeted protein degradation now spans four distinct mechanisms: classical PROTAC E3 ligase recruitment via cereblon, new E3 ligases like TRIM21 that selectively degrade aggregated proteins while sparing monomers, lysosomal degraders targeting extracellular proteins via bispecific antibodies, and induced proximity approaches enabling phosphorylation and protein stabilization beyond degradation.
✓MFN legislation risk for small biotechs: Trump's push to codify Most Favored Nation pricing into law poses a greater threat to small biotechs than large multinationals. Private White House deals use a definition benchmarked to the second-lowest price among eight industrialized nations — public legislation could impose a stricter definition across the entire industry with no negotiated carve-outs.
✓Pediatric PRV reauthorization near completion: The House included pediatric priority review voucher reauthorization through September 30, 2029 in a government spending bill. PRVs function as a zero-taxpayer-cost mechanism transferring capital from large pharma to small biotechs developing therapies for rare pediatric diseases, and are a prerequisite for gene and cell therapy development in ultra-rare conditions.

What It Covers

BioCentury This Week covers JPMorgan Healthcare Conference takeaways, GSK's $2.2B acquisition of Wrap Therapeutics targeting food allergies, next-generation targeted protein degradation technologies including TACs and lysosomal degraders, Trump's push to codify Most Favored Nation drug pricing into legislation, and pediatric priority review voucher reauthorization progress in Congress.

Key Questions Answered

•GSK's Wrap acquisition strategy: GSK paid $2.2B ($1.9B net of cash) for Wrap Therapeutics, a company that in-licensed its food allergy prophylaxis asset from Chinese firm JU just 13 months prior for $35M upfront plus ~$700M in milestones. The Phase 2b asset targets a dosing advantage over Xolair, with results expected within one year.
•China-to-West asset licensing model: Western pharma companies are actively licensing and acquiring assets originating from Chinese biotechs, but geopolitical barriers make full company acquisitions of Chinese firms effectively off the table. The practical playbook is to take the asset, not the company, avoiding regulatory and political entanglement while capturing innovation.
•TAC field expansion beyond proteasome: Next-generation targeted protein degradation now spans four distinct mechanisms: classical PROTAC E3 ligase recruitment via cereblon, new E3 ligases like TRIM21 that selectively degrade aggregated proteins while sparing monomers, lysosomal degraders targeting extracellular proteins via bispecific antibodies, and induced proximity approaches enabling phosphorylation and protein stabilization beyond degradation.
•MFN legislation risk for small biotechs: Trump's push to codify Most Favored Nation pricing into law poses a greater threat to small biotechs than large multinationals. Private White House deals use a definition benchmarked to the second-lowest price among eight industrialized nations — public legislation could impose a stricter definition across the entire industry with no negotiated carve-outs.
•Pediatric PRV reauthorization near completion: The House included pediatric priority review voucher reauthorization through September 30, 2029 in a government spending bill. PRVs function as a zero-taxpayer-cost mechanism transferring capital from large pharma to small biotechs developing therapies for rare pediatric diseases, and are a prerequisite for gene and cell therapy development in ultra-rare conditions.

Notable Moment

Novartis CEO Vas Narasimhan stated that MFN-style pricing constraints represent a permanent new normal, not a temporary political cycle. His expectation is that some European markets will see delayed launches, private-market-only access, or no launches at all — forcing a structural rethink of European drug pricing frameworks.

Know someone who'd find this useful?

Episode Transcript

Welcome to the BioCentury this week podcast. I hope our listeners who came out to San Francisco last weekend for the JPMorgan Healthcare Conference had a productive and fun week. San Francisco itself certainly showed up for the party with sunny skies, meetings in oddball spaces, a lot of pink on JPM Tuesday, and live music, and, dare I say, even a foosball table in the middle of Union Square. We'll talk about some of our takeaways from JPM. Plus, GSK is buying wrapped for 2,200,000,000.0, eyeing a food allergy opportunity. And after a decade of industry focus on pro tax, next generation induced proximity technologies are coming of age. We'll go tack to the future with senior biopharma analyst, Danielle Golovin. And we'll get the update from Steve Austin, our Washington editor, on what's happening in the politics and policy world. Among other things, president Donald Trump is seeking to codify his most favored nation drug pricing policy as part of his health care plan. And the house spending bill includes reauthorization of priority review vouchers. I'm Jeff Cranmer, executive editor here at BioCentury. And joining me to discuss all of this are my colleagues Simone Fishburne, editor in chief. Steve Usdin, Washington editor. And Danielle Golovin, senior biopharma analyst. Alright. Danielle, welcome to the podcast making your debut from the sunny East Coast Of Florida. Yes. Home of the famous Doondog. Oh, yes. Doondog. Danielle and I, are big fans of Doondog, which I can't recommend highly enough. It is over in Jupiter, Florida and has some of the best dogs and milkshakes around. There's kind of a mini biotech hub near you, Danielle. Isn't that the case? A little bit. A little bit. Yeah. A little bit happening. Alright. Well, you yourself, you know, you need to start it. Yes. You need to start it. Okay. Well, before we get started, this March, BioCentury is headed to Seoul to host its fifth East West Summit. Once again, coordinating the event with Bay Helix and McKinsey. Learn how to source innovation from Asia or accelerate your own pipeline by finding the right Asia partner at the three day event. Presenting company slots are just about sold out, but delegate tickets are still available. Get yours today. Go to biocenturyeastwest.com. And coming up later this week, we will have a special edition of the BioCentury this week podcast featuring Steven Hansen with his 2026 public markets preview. Alright. Simone, it was good to see you last week. Thanks for coming out my way. Did you have a good meeting? I did have a good meeting. There's a lot of talk about the weather being good. I came back via Houston, actually, for another meeting. Weather weather was good. I'm now in the nation's capital where it's good to be back, though temperatures are in the minus range, I think on almost every scale except maybe Kelvin. And despite all of that, I'm going to get back at my colleagues …

Get the full transcript (4,997 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all BioCentury This Week transcripts →